FDA denies approval of generic Lovenox

Novartis AG and biotechnology firm Momenta Pharmaceuticals' generic version of anti-clotting drug Lovenox has been rejected by the FDA due to concerns about the treatment's effect on the immune system. Momenta executives said they would work with the FDA to address their concerns.

View Full Article in:

Boston Globe (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC